Clinical Trial Detail

NCT ID NCT02185690
Title A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors University Health Network, Toronto, Novartis
Indications

lung large cell carcinoma

lung adenocarcinoma

Therapies

Binimetinib + Carboplatin + Pemetrexed

Age Groups: adult senior

Additional content available in CKB BOOST